Recent News

• 02.02.2026 - ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas
• 01.30.2026 - MAHA Action Media Hub
• 01.24.2026 - USA–Saudi Biotech Alliance Summit Marks a New Era in Healthspan, Immunotherapy, and Global Scientific Partnership
• 01.23.2026 - ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
• 01.22.2026 - ASCO GU
• 01.22.2026 - AUA 2026
• 01.20.2026 - ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer
• 01.20.2026 - Is the FDA BLOCKING Life Saving Cancer Treatments?
• 01.16.2026 - ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma
• 01.16.2026 - ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG

Recent Filings

• 01.26.2026 - 8-K Current report
• 01.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.20.2026 - 144 Report of proposed sale of securities
• 01.20.2026 - 144 Report of proposed sale of securities
• 01.16.2026 - 144 Report of proposed sale of securities
• 01.15.2026 - EX-99.1 EX-99.1
• 01.15.2026 - 8-K Current report